MUC16 and neoplasm: Additionally, our antibody showed a 13-fold higher internalization in MUC16-expressing OVCAR3 cells compared to negative-control SKOV3 cells in the first 2 h of incubation, and this internalization was 721-fold higher by the end of 48 h incubation, indicating the therapeutic potential of M16Ab via antibody-drug conjugates or the delivery of highly toxic radiation dose to the tumor site.